C4 Therapeutics Inc（CCCC）の財務CCCCC4 Therapeutics Inc

Evaluating the bottom line, C4 Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -397.88%, while the net margin is -355.90%. These profitability ratios, combined with a Return on Equity (ROE) of -48.14%, provide a clear picture of how effectively CCCC converts its operational activities into shareholder value.

In the context of the broader market, CCCC competes directly with industry leaders such as SGMO and ELTX. With a market capitalization of $383.85M, it holds a leading position in the sector. When comparing efficiency, CCCC's gross margin of 100.00% stands against SGMO's 100.00% and ELTX's N/A. Such benchmarking helps identify whether C4 Therapeutics Inc is trading at a premium or discount relative to its financial performance.

C4 Therapeutics has reported revenue growth, with $6.64 million generated in Q2 2026 from collaborations, up from $6.46 million the previous year. Despite this, the company continues to experience significant net losses, with a net loss of $23.63 million in Q2 2026.